Study points to new risk in gene therapy death of Terry Horgan

TerryHorganinhisfamily'sMontourFalls,N.Y.,home,inanundatedphoto.KateCollins/TheJournalviaAPLastOctob AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge




explore

author：knowledge    Page View：5
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： New oral drug delivery patch is modeled after octopus tentacles
Next article： Medicare proposal to cover medical devices draws a mixed reaction